Literature DB >> 15549303

Non-myeloablative stem cell transplantation for autoimmune diseases.

Richard K Burt1, Larissa Verda, Yu Oyama, Laisvyde Statkute, Shimon Slavin.   

Abstract

Treatment of life-threatening autoimmune diseases in animal models with induced or spontaneous autoimmune diseases can be accomplished by a 2-step procedure involving elimination of self-reactive lymphocytes with an immune ablative conditioning regimen followed by infusion of autologous or allogeneic stem cells, respectively. In animal models it was shown that using such a strategy, autoimmunity could be adequately controlled. It is speculated that de-novo development of the T and B cell repertoire from uncommitted progenitor cells in the presence of the autoantigens may be the best recipe for re-induction of self-tolerance, similarly to the normal ontogeny of the immune system during the induction of self tolerance in fetal stage. For both autologous and allogeneic hematopoietic stem cell transplantation, a non-myeloablative stem cell transplantation (NST) regimen may be used for safer lymphoablation rather than myeloablation. In addition, for allogeneic hematopoietic stem cell transplantation engraftment of disease resistant donor stem cells will alter the genetic predisposition towards autoimmune disease susceptibility.

Entities:  

Mesh:

Year:  2004        PMID: 15549303     DOI: 10.1007/s00281-004-0162-6

Source DB:  PubMed          Journal:  Springer Semin Immunopathol        ISSN: 0344-4325


  58 in total

Review 1.  Non-myeloablative stem cell transplantation for induction of host-versus-graft tolerance for adoptive immunotherapy of malignant and nonmalignant diseases and towards transplantation of organ allografts.

Authors:  S Slavin
Journal:  Transplant Proc       Date:  2002-12       Impact factor: 1.066

2.  Hematopoietic stem cell transplantation for severe and refractory lupus. Analysis after five years and fifteen patients.

Authors:  Ann E Traynor; Walter G Barr; Robert M Rosa; Julianne Rodriguez; Yu Oyama; Steven Baker; Mary Brush; Richard K Burt
Journal:  Arthritis Rheum       Date:  2002-11

3.  T cell-depleted autologous hematopoietic stem cell transplantation for multiple sclerosis: report on the first three patients.

Authors:  R K Burt; A E Traynor; B Cohen; K H Karlin; F A Davis; D Stefoski; C Terry; L Lobeck; E J Russell; C Goolsby; S Rosen; L I Gordon; C Keever-Taylor; M Brush; M Fishman; W H Burns
Journal:  Bone Marrow Transplant       Date:  1998-03       Impact factor: 5.483

4.  Relapses and progression of disability in multiple sclerosis.

Authors:  C Confavreux; S Vukusic; T Moreau; P Adeleine
Journal:  N Engl J Med       Date:  2000-11-16       Impact factor: 91.245

5.  Bone marrow transplantation in patients with gold-induced marrow aplasia.

Authors:  J L Baldwin; R Storb; E D Thomas; M Mannik
Journal:  Arthritis Rheum       Date:  1977-06

Review 6.  The role of interleukin-10 in autoimmune disease: systemic lupus erythematosus (SLE) and multiple sclerosis (MS).

Authors:  Amy M Beebe; Daniel J Cua; Rene de Waal Malefyt
Journal:  Cytokine Growth Factor Rev       Date:  2002 Aug-Oct       Impact factor: 7.638

7.  Familial scleroderma: HLA antigens and autoantibodies.

Authors:  M Hietarinta; S Koskimies; O Lassila; E Soppi; A Toivanen
Journal:  Br J Rheumatol       Date:  1993-04

8.  Predictors of survival in systemic sclerosis (scleroderma).

Authors:  R D Altman; T A Medsger; D A Bloch; B A Michel
Journal:  Arthritis Rheum       Date:  1991-04

9.  Long-term follow-up of patients with Crohn's disease. Relationship between the clinical pattern and prognosis.

Authors:  R G Farmer; G Whelan; V W Fazio
Journal:  Gastroenterology       Date:  1985-06       Impact factor: 22.682

Review 10.  High-dose immune suppression and autologous hematopoietic stem cell transplantation in refractory Crohn disease.

Authors:  Richard K Burt; Ann Traynor; Yu Oyama; Robert Craig
Journal:  Blood       Date:  2002-10-10       Impact factor: 22.113

View more
  5 in total

Review 1.  [Therapy of systemic sclerosis].

Authors:  M Meurer; P Rehberger
Journal:  Hautarzt       Date:  2007-10       Impact factor: 0.751

Review 2.  Treatment of refractory ITP and Evans syndrome by haematopoietic cell transplantation: is it indicated, and for whom?

Authors:  J E Vaughn; F Anwer; H J Deeg
Journal:  Vox Sang       Date:  2015-07-14       Impact factor: 2.144

Review 3.  Treatment of Crohn's disease complicated with myelodysplastic syndrome via allogeneic hematopoietic stem cell transplantation: case report and literature review.

Authors:  Changmei Hu; Liang Lv; Deliang Liu; Jirong Huo
Journal:  Clin J Gastroenterol       Date:  2014-05-22

4.  Human peripheral blood leucocyte non-obese diabetic-severe combined immunodeficiency interleukin-2 receptor gamma chain gene mouse model of xenogeneic graft-versus-host-like disease and the role of host major histocompatibility complex.

Authors:  M A King; L Covassin; M A Brehm; W Racki; T Pearson; J Leif; J Laning; W Fodor; O Foreman; L Burzenski; T H Chase; B Gott; A A Rossini; R Bortell; L D Shultz; D L Greiner
Journal:  Clin Exp Immunol       Date:  2009-07       Impact factor: 4.330

Review 5.  Risks, benefits, and therapeutic potential of hematopoietic stem cell transplantation for autoimmune diabetes.

Authors:  Carlos Eduardo Barra Couri; Maria Carolina de Oliveira; Belinda Pinto Simões
Journal:  Curr Diab Rep       Date:  2012-10       Impact factor: 5.430

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.